Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OQ5R
|
|||
| Former ID |
DIB002298
|
|||
| Drug Name |
IGN523
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1], [2] | |
| Company |
Igenica
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphocyte activation antigen 4F2 (SLC3A2) | Target Info | . | [3] |
| KEGG Pathway | Protein digestion and absorption | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathwhiz Pathway | Kidney Function | |||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| Reactome | Basigin interactions | |||
| Amino acid transport across the plasma membrane | ||||
| WikiPathways | Transport of inorganic cations/anions and amino acids/oligopeptides | |||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02040506) A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015 Aug 1;137(3):710-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.